MedTrace Logo

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

NCT04772547 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-07-23

Study results available
· View outcomes & findings →

Summary

This is a pilot trial of a single loading dose of vigabatrin in post-anoxic status epilepticus.

Conditions

  • Status Epilepticus, Electrographic
  • Coma

Interventions

DRUG

Vigabatrin Only Product

enteral medication administration, serial blood draws, and outcome assessment

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Thomas Jefferson University

    collaborator OTHER

  • American Heart Association

    collaborator OTHER

  • University of Florida

    lead OTHER

Principal Investigators

  • Carolina B Maciel, MD, MSCR · University of Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2023-06-07
Completion
2024-01-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04772547 on ClinicalTrials.gov